AFP and hepatocellular carcinoma: Among these combinations, the AFP/AFU panel outperformed the others and exhibited a greater diagnostic sensitivity and specificity for the differentiation of all-stage HBV-HCC and HCV-HCC patients from CH and LC patients [AUC: 0.835 (0.784–0.877), sensitivity: 69.1%, specificity: 87.4%] (Figure 4G).